Latest news with #Pfizer
Globe and Mail
7 hours ago
- Health
- Globe and Mail
Vitiligo Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight
DelveInsight's ' Vitiligo Treatment Market Insights, Epidemiology and Market Forecast – 2034 ' report delivers an in-depth understanding of Vitiligo, historical and forecasted epidemiology as well as the Vitiligo market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan. To know in detail about the Vitiligo market outlook, drug uptake, treatment scenario, and epidemiology trends, click here @ Vitiligo Treatment Market Size Key Takeaways from the Vitiligo Market Report In June 2025, Incyte Corporation announced a study to evaluate the safety and efficacy of ruxolitinib cream in pediatric participants with non-segmental vitiligo. In June 2025, Pfizer conducted a study to learn about the safety and effects of the study medicine ritlecitinib for the possible treatment of non-segmental vitiligo. Vitiligo causes white patches on your skin when the cells that give your skin color are destroyed. Nonsegmental means that it can affect both sides of the body, such as both knees and both hands. In June 2025, Vyne Therapeutics Inc. organized a Phase 2b Trial Evaluating the Efficacy, Safety & Pharmacokinetics of VYN201 Gel in the Treatment of Non-Segmental Vitiligo. According to the findings, the United States accounted for around 60% of the Vitiligo diagnosed Prevalent Cases in the 7MM in 2023. In EU4 and the UK, Germany contributed the highest patient share of vitiligo, followed by the UK. Whereas Spain contributed to the lowest patient share. As per the estimates, there were 493,000 treated cases of vitiligo in the 7MM in 2023. The leading Vitiligo Companies such as Incyte, AbbVie, Pfizer, Clinuvel, Inc., Clinuvel Pharmaceuticals, Bioniz Therapeutics, TAGCyx Biotechnologies, Temprian Therapeutics, Aclaris Therapeutics, TWi Biotechnology, Dermavant Sciences, Amgen, Pfizer, Incyte Corporation, and others Promising Vitiligo Pipeline Therapies such as OPZELURA (ruxolitinib cream), RINVOQ (upadacitinib), Ritlecitinib, Afamelanotide, Phimelanotide, BNZ-1, TAGX-0003, TT-01, ATI-1777, AC-1101, Cerdulatinib, AMG 714, Ritlecitinib, Ruxolitinib, and others. Get a Free sample for the Vitiligo Therapeutics Market Report @ Vitiligo Drugs Market Vitiligo Epidemiology Segmentation in the 7MM Vitiligo Prevalence Cases Vitiligo Type-specific Cases Vitiligo Diagnosed Prevalent Cases Vitiligo Treated Cases Download the report to understand which factors are driving Vitiligo epidemiology trends @ Vitiligo Prevalence Vitiligo Marketed Drugs OPZELURA (ruxolitinib cream): Incyte In July 2024, the US FDA approved a groundbreaking treatment for vitiligo, a chronic immune-mediated skin disorder characterized by depigmented white patches on the skin. The newly approved drug, OPZELURA, is a topical Janus kinase (JAK) inhibitor called ruxolitinib. This approval marks a significant milestone, as OPZELURA is the first FDA-approved pharmacologic treatment specifically designed to address repigmentation in vitiligo patients, particularly those with nonsegmental vitiligo, the most common form of the condition. OPZELURA works by targeting JAK1 and JAK2 receptors to decrease interferon gamma signaling by immune cells, thereby halting the destruction of melanocytes responsible for skin color. Vitiligo Emerging Drugs RINVOQ (upadacitinib): Abbvie Upadacitinib (ABT-494) is a JAK1 selective inhibitor being investigated to treat alopecia areata, ankylosing spondylitis, atopic dermatitis, axial SpA, Crohn's disease, giant cell arteritis, hidradenitis suppurativa (HS), psoriatic arthritis, rheumatoid arthritis, systemic lupus erthematosus (SLE), Takayasu arteritis, ulcerative colitis, and vitiligo. Currently, the drug is in Phase III for the treatment of vitiligo, for which primary completion date is December 2024. At the 2024 AAD Annual Meeting, late-breaking data showed that upadacitinib demonstrated clinically meaningful repigmentation of extensive vitiligo after 52 weeks, potentially offering a new and effective systemic treatment for non-segmental vitiligo. LITFULO (Ritlecitinib): Pfizer LITFULO (ritlecitinib) is considered a kinase inhibitor, meaning it prevents kinases, which are certain proteins in the immune system, from working properly. This in turn blocks the immune pathways that are thought to contribute to the development of autoimmune diseases, resulting in symptom improvements, such as repigmentation or stopping of disease progression in vitiligo. Currently, there is a Phase III Vitiligo Clinical Trial underway with an estimated completion date in June 2025. Depending on the results of that trial, ritlecitinib may be approved for vitiligo treatment. Discover more about therapies set to grab major Vitiligo market share @ Vitiligo Clinical Trials Assessment Vitiligo Treatment Market The Vitiligo Treatment Market Landscape is undergoing rapid transformation, marked by significant advancements anticipated in 2024 and beyond. With the introduction of FDA-approved topical therapies and the emergence of oral JAK inhibitors, dermatology is experiencing remarkable progress in managing this complex condition. These developments signify a promising future for vitiligo patients, reflecting the evolving strategies aimed at enhancing treatment efficacy and patient outcomes. Key Vitiligo Companies such as AbbVie, Incyte, Pfizer, and others are evaluating their lead candidates in different stages of clinical development, respectively. They aim to investigate their products for the treatment of vitiligo. Vitiligo treatment typically involves a combination approach, incorporating various topical therapies such as steroids, vitamin D analogues, and calcineurin inhibitors. While mono-therapy topicals have shown improvement, the most effective treatment strategy often involves a combination of phototherapy, oral antioxidants, and both oral and topical medications. This multifaceted approach addresses the complex nature of vitiligo and maximizes therapeutic outcomes. Driven by rising awareness and new treatment options, the vitiligo market is poised for steady growth in the coming years. Vitiligo Drugs and Companies OPZELURA (ruxolitinib cream): Incyte RINVOQ (upadacitinib): AbbVie Ritlecitinib: Pfizer Afamelanotide: Clinuvel, Inc. Phimelanotide - Clinuvel Pharmaceuticals BNZ-1: Bioniz Therapeutics TAGX-0003: TAGCyx Biotechnologies TT-01: Temprian Therapeutics ATI-1777: Aclaris Therapeutics AC-1101: TWi Biotechnology Cerdulatinib: Dermavant Sciences AMG 714: Amgen Ritlecitinib: Pfizer Ruxolitinib: Incyte Corporation Vitiligo Market Drivers Increasing awareness Demand for novel therapies Large patient pool and better healthcare infrastructure Vitiligo Market Barriers Patient compliance Chronic nature of the disease and long-term therapy Lack of adequate financial assistance & stringent regulatory procedure Download DelveInsight's latest report to gain strategic insights into upcoming Vitiligo Therapies and key Vitiligo Developments @ Vitiligo Market Drivers and Barriers, and Future Perspectives Scope of the Vitiligo Market Report Coverage- 7MM Study Period- 2020-2034 Vitiligo Companies- Incyte, AbbVie, Pfizer, Clinuvel, Inc., Clinuvel Pharmaceuticals, Bioniz Therapeutics, TAGCyx Biotechnologies, Temprian Therapeutics, Aclaris Therapeutics, TWi Biotechnology, Dermavant Sciences, Amgen, Pfizer, Incyte Corporation, and others Vitiligo Pipeline Therapies- OPZELURA (ruxolitinib cream), RINVOQ (upadacitinib), Ritlecitinib, Afamelanotide, Phimelanotide, BNZ-1, TAGX-0003, TT-01, ATI-1777, AC-1101, Cerdulatinib, AMG 714, Ritlecitinib, Ruxolitinib, and others. Vitiligo Therapeutic Assessment: Vitiligo current marketed and emerging therapies Vitiligo Market Dynamics: Vitiligo market drivers and Vitiligo market barriers Vitiligo Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Vitiligo Unmet Needs, KOL's views, Analyst's views, Vitiligo Market Access and Reimbursement Table of Contents 1 Key Insights 2 Vitiligo Market Report Introduction 3 Vitiligo Executive Summary 4 Key Events 5 Vitiligo Epidemiology and Market Forecast Methodology 6 Vitiligo Market Overview at a Glance 7 Disease Background and Overview: Vitiligo 8 Vitiligo Treatment and Management 9 Vitiligo Epidemiology and Patient Population in the 7MM 10 Patient Journey 11 Vitiligo Marketed Therapies 12 Vitiligo Emerging Therapies 13 Vitiligo: Seven Major Market Analysis 14 Vitiligo Unmet Needs 15 Vitiligo SWOT Analysis 16 Vitiligo KOL Views 17 Vitiligo Market Access and Reimbursement 18 Appendix 19 DelveInsight Capabilities 20 Disclaimer 21 About DelveInsight About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Yahoo
12 hours ago
- Business
- Yahoo
Pfizer (NYSE:PFE) Joins FIBRE Consortium To Advance Fibrosis Treatment Through Innovative Imaging
The recent formation of the FIBRE Consortium, a collaboration involving Pfizer and other pharmaceutical partners, aims to pioneer advancements in fibrotic disease management. Alongside this, Pfizer's submission of a New Drug Application for vepdegestrant to treat breast cancer and significant progress in colorectal and prostate cancer therapies were key developments. Over the past month, Pfizer's stock saw a price increase of 4%. The company's performance appeared aligned with market trends amid geopolitical tensions and fluctuations in oil prices, indicating resilience within the broader mixed market conditions. These recent strategic initiatives have likely provided a positive foundation. We've identified 3 possible red flags with Pfizer and understanding the impact should be part of your investment process. Uncover 17 companies that survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. The developments in Pfizer's strategic initiatives, specifically the formation of the FIBRE Consortium and the submission of the New Drug Application for vepdegestrant, could potentially enhance the company's revenue and earnings forecasts. These projects may strengthen Pfizer's position in the competitive pharmaceuticals landscape, especially as the company intensifies its focus on oncology. However, the ongoing threat of increased competition and reduced utilization of key drugs remain factors that may pressure revenue, possibly mitigating some of the positive impacts from the recent news. Over the past five years, Pfizer's total return, including share price and dividends, was a 1.05% decline, illustrating longer-term challenges despite short-term gains. On a one-year basis, the stock underperformed the US market, which achieved a 10.4% return, indicating some operational hurdles within the company. The recent strategic progress may offer potential relief if executed effectively. The stock's performance, with a recent monthly increase of 4%, places it in a unique position relative to the consensus analyst price target of US$29.24. The current share price of US$24.41 sits at a 22% discount to this target, hinting at potential upside according to more optimistic analysts. In contrast, some bearish analysts set a price target closer to US$24.57, suggesting that expectations are diverse. This disparity in views underscores the importance of closely monitoring how Pfizer's strategic developments influence its future performance and valuation. Jump into the full analysis health report here for a deeper understanding of Pfizer. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:PFE. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15 hours ago
- Business
- Yahoo
Pfizer vs BMY: Which Oncology Drugmaker Is a Better Choice for Now?
Pharma/biotech giants Pfizer PFE and Bristol Myers BMY boast of a dominant position in the lucrative oncology space. Oncology or cancer is one of the most sought-after areas in the pharma/biotech space. As the world at large continues to grapple with a significant increase in the number of cancer patients, the market for cancer medicines is expected to grow. Pfizer is one of the largest and most successful drugmakers in the field of oncology. Oncology sales comprise around 25% of its total revenues. Oncology is a key therapeutic area of focus for Bristol Myers, which is developing and delivering transformational medicines in this space. Both drugmakers have strong footholds in their respective target markets, delivering consistent returns to shareholders. In such a scenario, choosing one stock over another can be challenging. Let us delve into their fundamentals, potential growth prospects, challenges and valuation levels to make a prudent choice. Pfizer has an innovative oncology product portfolio of antibody-drug conjugates (ADCs), small molecules, bispecifics and other immunotherapies that treat a wide range of cancers, including certain types of breast cancer, genitourinary cancer and hematologic malignancies, as well as certain types of melanoma, gastrointestinal, gynecological and lung cancer. Approved drugs in the portfolio include Ibrance, Xtandi, Inlyta, Lorbrena, Bosulif, Braftovi, Mektovi, Orgovyx, Elrexfio and Talzenna. Among these, the breast cancer drug Ibrance is one of the top revenue generators. The acquisition of Seagen in December 2023 strengthened PFE's oncology portfolio by adding four ADCs — Adcetris, Padcev, Tukysa and Tivdak. This initiative boosted oncology sales in 2024 and the first quarter of 2025. Seagen also has some next-generation ADC candidates in its pipeline and their successful development should further strengthen its portfolio. PFE is working on the label expansion of many of its cancer drugs that should boost sales. Pfizer also has oncology biosimilars in its portfolio and markets six of them for cancer. Oncology biosimilars primarily include Retacrit, Ruxience, Zirabev, Trazimera and Nivestym. Pfizer is also advancing a robust pipeline of oncology candidates, with several entering late-stage development. By 2030, it expects to have eight or more blockbuster oncology medicines in its portfolio. Apart from oncology, Pfizer's portfolio has a variety of drugs and vaccines for diseases like COVID-19, inflammation & immunology diseases, rare diseases and migraine, among others. BMY is focused on extending and strengthening its leadership in immuno-oncology (IO), as well as diversifying beyond IO. Leading IO drug Opdivo, approved for several cancer indications, drives its oncology franchise along with Yervoy and Opdualag. The FDA recently granted approval to Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for subcutaneous use. Per BMY, this new subcutaneous formulation of Opdivo should help extend the reach and impact of its immuno-oncology franchise to patients into the next decade. Reblozyl, approved for first-line MDS-associated anemia, continues to drive market share within the larger first-line ring sideroblasts negative population. The CAR-T cell therapy Breyanzi is approved to treat the broadest array of B-cell malignancies. BMY has also been active on the acquisition front to expand its oncology portfolio/pipeline. In 2024, BMY acquired Mirati, a commercial-stage targeted oncology company, obtaining the rights to commercialize lung cancer medicine Krazati and to further develop several clinical assets, including PRMT5 Inhibitor. Krazati, a KRAS inhibitor, is approved for second-line non-small cell lung cancer (NSCLC) and is in clinical development with a PD-1 inhibitor for first-line NSCLC. It is also FDA approved for advanced or metastatic KRAS-mutated colorectal cancer with cetuximab. In addition, PRMT5 Inhibitor is a potential first-in-class MTA-cooperative PRMT5 inhibitor, which is advancing to the next stage of development. The acquisition of RayzeBio, a leader in the field of radiopharmaceuticals for solid tumor oncology, provided BMY with RYZ101, a late-stage asset, an investigational new drug engine and in-house manufacturing capabilities. In 2022, BMY acquired Turning Point and added lead asset, repotrectinib, and other clinical and pre-clinical stage assets to its pipeline. Repotrectinib was approved by the FDA in November 2023 and is marketed under the brand name Augtyro. Augtyro, a kinase inhibitor, is indicated for the treatment of adult patients with locally advanced or metastatic ROS1-positive NSCLC. It is also intended for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have NTRK gene fusion, are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy. Bristol Myers is also focused on developing drugs with presence in hematology, immunology, cardiovascular, neuroscience and other therapeutic areas. The Zacks Consensus Estimate for PFE's 2025 sales implies a year-over-year decrease of 0.6%, and that for earnings per share (EPS) suggests a year-over-year decline of 1.61%. EPS estimates for 2025 and 2026 have moved north in the past 60 days. Image Source: Zacks Investment Research The Zacks Consensus Estimate for BMY's 2025 sales implies a year-over-year decrease of 4.13% while that for EPS suggests an increase of 487.83%. The extraordinary EPS growth rate is attributed to an extremely low EPS figure in 2024 due to acquisition expenses. EPS estimates for both 2025 and 2026 have moved south in the past 60 days. Image Source: Zacks Investment Research From a price-performance perspective, PFE has performed better than BMY so far this year. Shares of PFE have declined 6.8%, while those of BMY have lost 15.4%. The large-cap pharma industry has declined 0.3% in the said period. Image Source: Zacks Investment Research From a valuation standpoint, we use the P/E ratio of the large-cap pharma industry to compare these companies. Going by the same, PFE is slightly more expensive than BMY. PFE's shares currently trade at 7.77X forward earnings, higher than 7.22 for BMY. Image Source: Zacks Investment Research PFE and BMY's attractive dividend yield is a strong positive for investors. However, PFE's dividend yield of 7.2% is higher than BMY's 5.29%. Large pharma/biotech companies are generally considered safe havens for investors interested in this sector. However, with both PFE and BMY stocks currently carrying a Zacks Rank #3 (Hold), choosing one over the other is a complex task. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. PFE has a strong and diverse portfolio but faces challenges like declining sales of its COVID-19 products and U.S. Medicare Part D headwinds in 2025. Several of its key products face patent expirations. Nonetheless, drugs like Vyndaqel, Padcev and Eliquis, and newly acquired products should continue to drive top-line growth. BMY's efforts to revive the top line in the face of generic challenges for key drugs are commendable. However, we believe there is still time before the efforts reap harvest for the company. The outlook for 2025 indicates challenges as of now. Hence, PFE is a better pick at present (despite its slightly pricey valuation), primarily due to the diversity of its portfolio and higher dividend yield compared to BMY. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report Pfizer Inc. (PFE) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
16 hours ago
- Business
- Globe and Mail
Pfizer vs BMY: Which Oncology Drugmaker Is a Better Choice for Now?
Pharma/biotech giants Pfizer PFE and Bristol Myers BMY boast of a dominant position in the lucrative oncology space. Oncology or cancer is one of the most sought-after areas in the pharma/biotech space. As the world at large continues to grapple with a significant increase in the number of cancer patients, the market for cancer medicines is expected to grow. Pfizer is one of the largest and most successful drugmakers in the field of oncology. Oncology sales comprise around 25% of its total revenues. Oncology is a key therapeutic area of focus for Bristol Myers, which is developing and delivering transformational medicines in this space. Both drugmakers have strong footholds in their respective target markets, delivering consistent returns to shareholders. In such a scenario, choosing one stock over another can be challenging. Let us delve into their fundamentals, potential growth prospects, challenges and valuation levels to make a prudent choice. The Case for Pfizer Pfizer has an innovative oncology product portfolio of antibody-drug conjugates (ADCs), small molecules, bispecifics and other immunotherapies that treat a wide range of cancers, including certain types of breast cancer, genitourinary cancer and hematologic malignancies, as well as certain types of melanoma, gastrointestinal, gynecological and lung cancer. Approved drugs in the portfolio include Ibrance, Xtandi, Inlyta, Lorbrena, Bosulif, Braftovi, Mektovi, Orgovyx, Elrexfio and Talzenna. Among these, the breast cancer drug Ibrance is one of the top revenue generators. The acquisition of Seagen in December 2023 strengthened PFE's oncology portfolio by adding four ADCs — Adcetris, Padcev, Tukysa and Tivdak. This initiative boosted oncology sales in 2024 and the first quarter of 2025. Seagen also has some next-generation ADC candidates in its pipeline and their successful development should further strengthen its portfolio. PFE is working on the label expansion of many of its cancer drugs that should boost sales. Pfizer also has oncology biosimilars in its portfolio and markets six of them for cancer. Oncology biosimilars primarily include Retacrit, Ruxience, Zirabev, Trazimera and Nivestym. Pfizer is also advancing a robust pipeline of oncology candidates, with several entering late-stage development. By 2030, it expects to have eight or more blockbuster oncology medicines in its portfolio. Apart from oncology, Pfizer's portfolio has a variety of drugs and vaccines for diseases like COVID-19, inflammation & immunology diseases, rare diseases and migraine, among others. The Case for Bristol Myers BMY is focused on extending and strengthening its leadership in immuno-oncology (IO), as well as diversifying beyond IO. Leading IO drug Opdivo, approved for several cancer indications, drives its oncology franchise along with Yervoy and Opdualag. The FDA recently granted approval to Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for subcutaneous use. Per BMY, this new subcutaneous formulation of Opdivo should help extend the reach and impact of its immuno-oncology franchise to patients into the next decade. Reblozyl, approved for first-line MDS-associated anemia, continues to drive market share within the larger first-line ring sideroblasts negative population. The CAR-T cell therapy Breyanzi is approved to treat the broadest array of B-cell malignancies. BMY has also been active on the acquisition front to expand its oncology portfolio/pipeline. In 2024, BMY acquired Mirati, a commercial-stage targeted oncology company, obtaining the rights to commercialize lung cancer medicine Krazati and to further develop several clinical assets, including PRMT5 Inhibitor. Krazati, a KRAS inhibitor, is approved for second-line non-small cell lung cancer (NSCLC) and is in clinical development with a PD-1 inhibitor for first-line NSCLC. It is also FDA approved for advanced or metastatic KRAS-mutated colorectal cancer with cetuximab. In addition, PRMT5 Inhibitor is a potential first-in-class MTA-cooperative PRMT5 inhibitor, which is advancing to the next stage of development. The acquisition of RayzeBio, a leader in the field of radiopharmaceuticals for solid tumor oncology, provided BMY with RYZ101, a late-stage asset, an investigational new drug engine and in-house manufacturing capabilities. In 2022, BMY acquired Turning Point and added lead asset, repotrectinib, and other clinical and pre-clinical stage assets to its pipeline. Repotrectinib was approved by the FDA in November 2023 and is marketed under the brand name Augtyro. Augtyro, a kinase inhibitor, is indicated for the treatment of adult patients with locally advanced or metastatic ROS1-positive NSCLC. It is also intended for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have NTRK gene fusion, are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy. Bristol Myers is also focused on developing drugs with presence in hematology, immunology, cardiovascular, neuroscience and other therapeutic areas. A Look at Estimates: PFE vs BMY The Zacks Consensus Estimate for PFE's 2025 sales implies a year-over-year decrease of 0.6%, and that for earnings per share (EPS) suggests a year-over-year decline of 1.61%. EPS estimates for 2025 and 2026 have moved north in the past 60 days. PFE's Estimate Movement The Zacks Consensus Estimate for BMY's 2025 sales implies a year-over-year decrease of 4.13% while that for EPS suggests an increase of 487.83%. The extraordinary EPS growth rate is attributed to an extremely low EPS figure in 2024 due to acquisition expenses. EPS estimates for both 2025 and 2026 have moved south in the past 60 days. BMY's Estimate Movement Price Performance and Valuation of PFE and BMY From a price-performance perspective, PFE has performed better than BMY so far this year. Shares of PFE have declined 6.8%, while those of BMY have lost 15.4%. The large-cap pharma industry has declined 0.3% in the said period. From a valuation standpoint, we use the P/E ratio of the large-cap pharma industry to compare these companies. Going by the same, PFE is slightly more expensive than BMY. PFE's shares currently trade at 7.77X forward earnings, higher than 7.22 for BMY. PFE and BMY's attractive dividend yield is a strong positive for investors. However, PFE's dividend yield of 7.2% is higher than BMY's 5.29%. Which Stock Is a Better Pick for Now? Large pharma/biotech companies are generally considered safe havens for investors interested in this sector. However, with both PFE and BMY stocks currently carrying a Zacks Rank #3 (Hold), choosing one over the other is a complex task. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. PFE has a strong and diverse portfolio but faces challenges like declining sales of its COVID-19 products and U.S. Medicare Part D headwinds in 2025. Several of its key products face patent expirations. Nonetheless, drugs like Vyndaqel, Padcev and Eliquis, and newly acquired products should continue to drive top-line growth. BMY's efforts to revive the top line in the face of generic challenges for key drugs are commendable. However, we believe there is still time before the efforts reap harvest for the company. The outlook for 2025 indicates challenges as of now. Hence, PFE is a better pick at present (despite its slightly pricey valuation), primarily due to the diversity of its portfolio and higher dividend yield compared to BMY. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Bristol Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report
New York Times
a day ago
- Business
- New York Times
This Loophole Buried in Trump's Bill Is Anything but Beautiful
It is hard to think of a less coherent pair of policies: President Trump's tax policy encourages the very offshoring that his tariffs are intended to stop. Take the more than $600 billion pharmaceutical industry. Over the past few months, Mr. Trump and his associates have repeatedly criticized companies' moves to offshore much drug making, particularly to Ireland. 'We can't be beholden and rely upon foreign countries for fundamental things that we need,' Commerce Secretary Howard Lutnick said on April 13. But the tax incentives in Mr. Trump's 2017 tax and spending package helped generate this problem in the first place — a problem that would continue under the Republican bill under consideration. Mr. Trump's Tax Cuts and Jobs Act created a loophole that made it far more profitable for the pharmaceutical giants, including Eli Lilly, Pfizer, Johnson and Johnson and Merck, to manufacture some of their most profitable drugs in Ireland. Unsurprisingly, that is what happened, with America's imports of pharmaceuticals soaring to $250 billion in 2024, way up from $110 billion back in 2016. American firms now report earning about $350 billion in profits annually in the world's major centers of corporate tax avoidance, which include Ireland, Luxembourg, Singapore and a handful of others. And while the major drug companies have mastered the art of taking advantage of the loopholes created by the 2017 law, semiconductor equipment producers and other Big Tech companies use the same special tax break. Fortunately, it isn't too late to make sensible changes that would raise revenue and get rid of this strange incentive. Republicans tend to blame Ireland's lower corporate tax rate for the proliferation of corporate tax avoidance, but the real incentive comes from this obscure corner of our tax code. It offers a far-lower 10.5 percent tax rate for global profits if a global firm moves the profits from its intellectual property offshore. The tax rate for domestic profits, in contrast, is 21 percent. The tax break was created by Republicans who were searching for a compromise that would stop companies from moving their headquarters overseas without fully ending tax competition and the associated pressure on U.S. corporate tax rates. Want all of The Times? Subscribe.
